Oppenheimer Just Upgraded Intuitive Surgical Stock. Here's Why.

Oppenheimer upgraded Intuitive Surgical (ISRG) to Outperform with a $500 price target, projecting a 24.6% upside from current levels. The analysts anticipate the company to maintain its leading position in the market despite competition, driven by the growth of robotic surgeries and AI integration. Intuitive is creating an AI-driven capability stack from real-world surgical data for advanced vision-language and reasoning models.

Elon Musk's short-selling strategy has seen enormous profits, while Alphabet's Gemini project aims to double Google's stock value. Despite headwinds like elective surgery volume concerns, a da Vinci component recall, and competition, Intuitive's stock has faced a 16.8% decline over the past 52 weeks and a 29.15% drop year-to-date.

The forward-adjusted price-to-earnings (non-GAAP) ratio is higher than the industry average. For Q2, revenue grew 18.5% YOY to $2.89 billion, driven by instrument and accessory sales, while da Vinci and Ion procedures saw a 16% YOY increase globally. Intuitive expects 13.5% to 15.5% da Vinci procedure growth and non-GAAP gross profit margins of 68% to 69% for fiscal 2026.

Wall Street remains bullish on Intuitive Surgical, with a Strong Buy consensus rating and a $480.93 price target, representing a 19.85% upside.